Enhertu is expected to break HER2 positive colorectal cancer treatment2021-11-26 00:17:09 5 ℃
Author: Hong Kong Dian An Medical Center
Founded in 1964, the US Clinical Tumor Society (ASCO) is a world leading tumor academic organization that provides professional organizations with medical and tumor professional services for cancer patients.
The annual ASCO annual meeting is the highest level of clinical tumors. Many important research discovery and clinical trial results will be released at the ASCO annual meeting. The American Society Of Clinical Oncology, ASCO annual meeting is over, and the following information on rectal cancer is summarized:
Normal colorectal cancer is the third largest common cancer in the world, and it is also the second common lethal cancer. For patients with metastatic colorectal cancer after a first-line treatment, the subsequently optional treatment is limited, and the patient has a disease torture, and the prognosis is extremely poor.
Destiny-CRC01 confirmed the role of ENHERTU (DS-8201) in HER2 overexpressing colorectal cancer.
2% ~ 3% of colorectal cancer presence HER2 amplification / overtrece. The DS-8201 is an antibody coupling agent targeted HER2, and this year ASCO released the DS-8201 latter Treatment of Destiny-CRC 01 studies of patients with colorectal cancer patients.
DestinY-CRC 01 is an open label II study. Patients with colorectal cancer receiving 2 ≥ line treated are divided into three queues, A (n = 53): HER2 IHC 3+ or IHC 2 + / ISH +; B (n = 7): IHC 2 + / ISH-; C (N = 18): IHC 1+, patients accept DS-8201 treatment, the main study end is ORR.
The results show that the confirmation of queue A is 45.3%, DCR is 83.0%, the median reaction duration (DURATION OF RESPONSE, DOR) 7.0 months, median PFS 6.9 months, median OS 15.5 months. The ORR of patients who have received anti-HER2 treatment were 43.8%, and IHC3 + patients were 57.5%. Queue B and Queue C Medium PFS 2.1 months and 1.4 months, median OS 7.3 months and 7.7 months. ≥ 3 TEAE is 65.1%, the most common AE is bone marrow inhibition and gastrointestinal reactions.
DS-8201 shows good activity and continuous reactions, safety, and uniform, with the result of the DS-8201 for HER2 overexpression colorectal cancer patients.
There is currently no batch of specific therapeutic drugs for patients with HER2 positive colorectal cancer , and the unique advantage of Enhertu in tumor relief rate and disease control rate will be expected to break HER2 positive colorectal cancer treatment, for the majority Patients bring new hopes.
This article is reproduced from other websites, does not represent health borders and positions. If there is any content and picture of the copyright objection, please contact us in time (email: [email protected])
Guess you like
- 2021-11-29Allergic rhinitis, spleen deficiency!One party, strengthen the spleen nose, the morn sneezing, please laugh
- 2021-11-28"Cell Subsidiary" has a milestone study: virus delivery CRISPR-Cas9 infected intestinal microorganism proves the potential of microbial group gene editing
- 2021-11-28Chen Yuxi: Minimally invasive valve technology is comprehensive, old-lived, high-risk surgery, driving
- 2021-11-2853-year-old man, in the daytime ECG, heart infarction at night!How to avoid tragedy again
- 2021-11-28Reproduce local epidemic!Many hospitals emergency stop
- 2021-11-27High school students, low back pain, foot paste, is old injuries
- 2021-11-27Low back pain, relying on lumbar and lumbar muscle strain, nearly half of people suffering from intervertebral tray
- 2021-11-27People's Daily: Just 4 steps from fatigue to cancer!You are the grass of the unit, but the family's day!
- 2021-11-27Obesity Management Guide in Kidney Transplantation Patients in European Kidney Association!
- 2021-11-26Repeating the kidney anti-aging series - afraid of blood vessel aging problems?Have a good trick
- Strong pay attention!Qingjin group CP kitchen should not read,
- Too!Sichuan's college birthday received 1 billion "super gift package"
- Gastric cancer surgery is not one for all, there is still recurrence risk, and postpartum follow-up should pay attention
- When dealing with male patient "privacy", is the female nurse?Deputy nurses may say the truth
- Long-term vegetarian food contribute to deteriogen?Creatinine rises, kidney diet should pay attention to "2 2 忌"
- Beautiful "surprise" - I meet with hooks
- What should I do if my baby has a cough?
- "It" is the best weight loss product, squeezed to oil, easy to get rid of the big belly, the skin is more young
- US Health and China's Thoracic Surgery Lung Cancer Prevention and Control Alliance reached a strategic cooperation to build lung cancer to prevent and control
- Anko's anti-tumor innovation drugs were approved by clinical trials